Company / Financials
Twist Bioscience Corp Financials
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
-
FY2025
Net Income
-$77.7M
FY2025 · +62.8% YoY
Profit Margin
-
FY2025 · net income / revenue
ROE
-16.4%
FY2025 · return on equity
Total Assets
$641.9M
FY2025
Total Debt
-
FY2025
Equity
$473.0M
FY2025
ROA
-12.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Net Income HistoryProfit after all expenses and taxes-$77.7M+62.8% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$185.6M+3.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$136.3M+38.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$247.0M+13.1% YoYR&D Expense HistoryResearch and development spending$80.3M-11.6% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$719.0K+28.4% YoYEPS (Basic) HistoryBasic earnings per share-$1.30+63.9% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.30+63.9% YoYShares Outstanding HistoryWeighted average diluted shares outstanding59.8M+3.1% YoY